Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
Lingfang Xia(Fudan University Shanghai Cancer Center), Xiaohua Wu(Fudan University Shanghai Cancer Center), Quanren Wang(Jiangsu Hengrui Medicine (China)), Yunong Gao, Rong Sun(Jiangsu Hengrui Medicine (China)), Yu Zhang(Wannan Medical College), Qi Zhou(Chongqing University), Ge Lou(Harbin Medical University), Jin Peng(Qilu Hospital of Shandong University), Huirong Shi(Zhengzhou University), Xianfeng Zhou(Jiangsu Hengrui Medicine (China)), Mei Pan(First Affiliated Hospital of Xiamen University), Jianqing Zhu, Li Wang(China Three Gorges University), Wenjing Hu
Cited by 39
Related Papers
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
Exosomes derived from mesenchymal stem cells reverse EMT via TGF-β1/Smad pathway and promote repair of damaged endometrium
|Stem Cell Research & Therapy|2019|294
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G
|Cancer Letters|2008|216